123 results about "Intra operative radiotherapy" patented technology

A system and method for immobilization of the human breast in a prone position during imaging and radiotherapy. The system includes a vacuum-assisted breast immobilization cup comprising two layers joined together with an air space between. The inner layer has densely perforated holes while the outer layer is airtight. When a negative vacuum is applied to the intermediate airspace the breast tissue is sucked against the mesh wall of the inner layer to preventing sliding. In addition, the cup assembly is locked into a fixed position against the patient torso via a body fixture, as well as against the patient support structure. The established geometric relationship among the cup, chest wall, imaging / treatment table or couch may be accurately repeated. The system further includes a three-dimensional localization system to uniquely place the breast in a coordinate system having fixed geometric relationship with the breast immobilization cup.

An apparatus and method for shielding non-target tissues and organs during thermotherapy, brachytherapy or other treatment of a diseased target tissue. The apparatus includes a catheter shaft having input and output lumens and at least one inflatable balloon. A plurality of input lumens within the catheter shaft allows the passage of liquid or gas through an input port and into the interior of the balloon thereby inflating the balloon. The gas or liquid can then be cycled through the inflated balloon through an output port and output lumen and out of the catheter shaft. Temperature sensors or other sensors may be attached to the balloon or catheter to monitor temperature or other conditions at the treatment site. The catheter is positioned between the target tissue or organ and sensitive non-target tissues in proximity to the target tissue and inflated causing a physical separation of tissues as well as a physical shield.

In some embodiments, a method includes receiving, in a processor, information indicative of (i) a treatment plan defining planned treatment beams, (ii) a patient volume relative to a reference, (iii) ideal intersections of the planned treatment beams with the patient volume at the time the patient is to be treated, (iv) any constraints that prevent achievement of the recommended repositioning using only the patient support, (v) an allowable change to a gantry position from a planned value and an allowable change to a collimator position from a planned value; defining, in the processor, a plurality of alternatives based at least in part on the information indicative of any constraints of the patient support and the information indicative of allowable movement of the gantry and collimator, each alternative defining a modified patient support position and modified beams, each modified beam being based at least in part on a respective one of the planned treatment beams, the change to the position of the gantry for the respective planned treatment beam and the change to the position of the collimator for the respective planned treatment beam; determining, in the processor, for each modified beam of each alternative, an intersection of the patient volume and the modified beam, with the patient volume positioned on the patient support and the patient support having the modified patient support position defined by the alternative; and defining, in the processor, for each alternative, a measure of difference between the ideal intersections and the intersections for the modified beams of the alternative.

Portal images are combined with 3D ultrasound to determine adjustments to patient treatment parameters. The images are acquired while the patient is in an initial position, and the images are registered to a treatment coordinate system. The images are combined and outlines of anatomical structures are superimposed on the portal images, resulting in new portal images that incorporate the anatomy extracted from the ultrasound. The enhanced portal images are used to identify modifications to the treatment parameters.

A fast semi-automatic prostate contouring method is provided using model-based initialization and an efficient Discrete Dynamic Contour (DDC) for boundary refinement. The user initiates the process of the preferred embodiment by identifying four (4) points on the prostate boundary, thereby scaling and shaping a prostate model, and then the final prostate contour is refined with a DDC. The method of the present invention has particular application during the pre-implant planning phase of a brachytherapy procedure. However, this method also has uses in any phase of dose planning in the brachytherapy procedure or any other therapy approach.

Brachytherapy apparatus and methods for performing brachytherapy employing expandable members with at least one external fixation element, offering precise therapy due to rotational and / or longitudinal stability of the expandable member.

The invention discloses a contour perception multi-organ segmentation network construction method based on class-by-class convolution operation. The contour perception multi-organ segmentation networkconstruction method comprises the following steps: 1, performing region coarse segmentation and edge detection on multiple organs of the abdomen; 2, introducing a semantic-guided class-by-class multi-scale attention mechanism; step 3, performing class-by-class fusion of multi-branch information; step 4, performing introduction of multi-task loss. According to the invention, the advantages of a convolutional neural network and a gated recurrent neural unit are utilized, and for the characteristics and difficulties of a multi-organ segmentation task, via the contour information assisted multi-scale feature extraction, a class-by-class multi-scale semantic attention mechanism, a class-by-class cavity convolution fusion mechanism and a plurality of loss functions can be introduced to relievethe inter-class imbalance problem of organs; multi-organ segmentation is performed on a three-dimensional CT image more efficiently and accurately, and the advantages of the invention are verified ona data set containing 14 types of organ labels; the invention can be widely applied to computer-aided diagnosis and treatment application, such as endoscopic surgery, interventional therapy and radiotherapy plan making.

A toroidal brachytherapy balloon is provided that fits over any brachytherapy applicator and reproducibly positions the applicator on every use.

The invention discloses an individual near-distance treatment source applicator and a manufacturing method thereof and belongs to the field of medical apparatus and instruments. The individual near-distance treatment source applicator comprises a source applicator tube. Source applicator line ducts which are axially communicated to two ends of the source applicator tube are formed in the annular end face of the source applicator tube. Two ends of the source applicator tube are a focus treatment end and a fixing end respectively. The focus treatment end is connected with an individual planting sleeve which allows the source applicator line ducts to be exposed and is matched with a focus. The source applicator has the advantages that the source applicator is matched with the height of the anatomical contour of the vagina, the fornix and the like of an individual patient and can closely attach to the focus area, the source applicator can have a plurality of source applicator line ducts, the positions of the source applicator line ducts can be adjusted according to the growing positions, sizes and shapes of tumors, and individual near-distance radiotherapy is achieved.

Expandable devices for placement within a patient comprising an elastomeric member in contact with at least one fiber that provide non-differential expansion. Brachytherapy apparatus and methods for performing brachytherapy employing expandable devices comprising an elastomeric member in contact with at least one fiber that provide non-differential expansion.

Methods for forming a prostate brachytherapy simulator are provided. A method comprises forming a molded rectum model between tubes secured to a base component of a container. The base component has a first open-bottomed cup that opens to an exterior of the container and a second cup that contains the first open-bottomed cup. The method also comprises forming a molded prostate model from recyclable materials. Additionally, the method comprises placing the prostate model relative to the rectum model. The method also comprises providing a gel-based environment that surrounds the rectum model and the prostate model within a container.

Electromedical apparatus for intraoperative radiotherapy via a linac. It includes an arm in which, at an extremity thereof, an oscillator is assembled which generates electromagnetic waves, and which supports, at an opposite extremity thereof, a radiating head in which a linac is assembled, emitting at its output an electron beam, supplied by the oscillator through a guiding structure. The apparatus includes a first and a second rotary couplings, respectively including a fixed portion and a mobile portion, endowed with sensors of the angular position of the mobile portions, which support the radiating head on the arm in roll and pitch motion. The guiding structure includes three separate rigid waveguides, of which one at the output of the oscillator and one of input to the linac, and an intermediate one therebetween, which connects them, with the heads of which they are respectively connected through the first and the second rotary couplings.

The invention relates to a solid tumors-curing Lapatinib sustained-release implant, which is characterized in that the sustained-release implant contains effective anti-tumor dose of Lapatinib, sustained-release auxiliary material and a certain amount of sustained-release regulator. Solid tumors consist of lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic cancer, bladder cancer and colorectal cancer. The sustained-release auxiliary materials are mainly one or mixture of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate) and poly (L-lactide-co-propyl phosphate). When the sustained-release auxiliary materials are degrading and absorbed, Lapatinib is slowly released into tumor part, thus while reducing toxic reaction of the whole body, the sustained-release auxiliary materials can sustain concentration of effective drug at the tumor part. Placing the anti-tumor sustained-release implant at the tumor part can not only reduce toxic reaction of the whole body of Lapatinib, but also improve drug concentration at the tumor part and enhance treatment effects of nonspecific treatments, such as chemotherapeutics, radiotherapy, etc.

The invention discloses a high-fidelity belly deformation mold for verifying precision of a deformable registration algorithm and a preparing method thereof. The preparing method for the high-fidelity belly deformation mold comprises the following steps of 1), preparing a three-dimensional mold which has high similarity to the outer contour of human body belly organs according to a computed tomography (CT) image of a belly tumor patient; 2) preparing simulated organs with CT numbers which approach the CT numbers of the organs; 3) preparing a simulated rigid bone; and 4) preparing a belly outer contour mold, placing the simulated organs and the simulated rigid bone into the mold, injecting PVC polymerization solution for performing injection molding, and arranging marking points and thermoluminescence agent films. The main organs in the mold have CT numbers which are similar with the CT number of human body organs and can simulate deformation of belly organs in a relatively real manner. Through arranging marking points and the thermoluminescence agent films in organs and portions among the organs, geometrical precision verification of the deformable registration algorithm and agent superposing precision verification in adaptive radiotherapy can be performed. High mold resilience and high reproducibility after deformation are realized.

The invention relates to a sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of bortezomib and sustained-release excipients. The solid tumor includes brain tumor, liver cancer, lung cancer, oesophagus cancer, gastric cancer, breast cancer, pancreatic cancer, thyroid cancer, nasopharyngeal cancer, ovarian cancer, endometrial cancer, cervical cancer, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, skin cancer, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma rooted at a peripheral nervous system, mucosa, glands, blood vessels, bone tissues and lymph nodes. The sustained-release excipients are mainly a biological polymer which is dissoluble and can be degraded and absorbed, in the degradation and absorption process of which carmustine is sustainedly released to part of the tumor, thus the entire toxicity of the carmustine is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the carmustine but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.

The invention discloses a mammary gland positioning part and a mammary gland positioning apparatus. The mammary gland positioning part comprises a base body provided with a suction structure for sucking a mammary gland up; and a cavity for fixing the sucked mammary gland is formed at one side, facing the mammary gland, of the base body. Because of the suction structure arranged at the base body ofthe mammary gland positioning part, the mammary gland positioning part is fixed at a breast firmly by the suction effect of the suction structure. The base body has a simple structure and the operation becomes convenient. Meanwhile, the cavity for fixing the sucked mammary gland is arranged at the base body, so that the mammary gland is fixed stably. The mammary gland positioning part is used forsucking up the mammary gland of the patient, so that the lesion mammary gland can be kept away from the heart and lung while the patient does not need to lie prostrate. Therefore, the injuries of thenormal heart and lung tissues by the rays during the radiotherapy can be reduced and the sequel of radiotherapy is reduced.

The invention discloses a method for calculating the invasion probability of a tumor clinical target area based on a hidden Markov model. The frequency of joint appearance of grid points in the three-dimensional tumor area is used to obtain the corresponding correlation rules; the primary tumor data of the new patient is read in, and the distance transformation is used to obtain the spatial distance from each voxel point to the primary tumor area; The probability of the primary tumor area is set as 1, and the invasion probability of each voxel point is related to the probability of adjacent voxels and the probability of the last observed state, and iteratively calculates outward from the primary tumor area; finally, all voxels are calculated The probability of a point being invaded by a tumor. The invention can assist the formulation of clinical radiotherapy plans, realize the automatic determination of the range of clinical radiotherapy target areas with different emission doses, reach the delineation standard for clinical application, and improve the working efficiency of doctors.

The present disclosure provides methods of increasing proliferation of adult salivary stem cells. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with an aldehyde dehydrogenase (ALDH) agonist. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells in an indi vidual undergoing radiotherapy for head and neck cancer.

A system and a method are provided for use in brachytherapy for fast and efficient preloaded needle service without the need of third-party vendors, using sterile seeds, spacers, needles and automated sterile components loading device in an aseptic environment. The system and method may be used in the treatment of, for example, prostate cancer.

The invention provides an automatic delineation method for organs at risk in pelvic radiotherapy. The automatic delineation method for the organs at risk in the pelvic radiotherapy synchronously carries out semi-supervised learning of the same convolutional neural network model through CT images of external irradiation and intracavitary irradiation for cervical cancer, synchronously; and thus, delineation accuracy under the same data size is raised with working efficiency and delineation consistency of medical workers improved, thereby improving accuracy of radiotherapy for cervical cancer.

The invention relates generally to methods of using a thiol-Michael addition hydrogel for providing intracavitary brachytherapy and / or displacing tissue and organs. The thiol-Michael addition hydrogel may be used as a packing material and an attenuation material for intracavitary brachytherapy applications. The invention also relates generally to a brachytherapy applicator, which may be used in conjunction with the thiol-Michael addition hydrogel and methods thereof. The invention also relates to a kit comprising at least one container containing the precursor materials of the thiol-Michael addition hydrogel.

Provided is a method for analyzing the prognosis of cervical cancer according to the human papillomavirus (HPV) DNA integration pattern. The method of analyzing the prognosis of cervical cancer according to the human papillomavirus DNA integration pattern of the present invention enables an observation of the HPV DNA integration pattern with accuracy and convenience via in situ hybridization (ISH) compared to qPCR analysis. Since the prognosis of cervical cancer having the tumors with an episomal pattern and an integrated pattern can be significantly distinguished when the HPV DNA integration patterns are classified by the above method, the survival rate after radiotherapy of cervical cancer, and in particular invasive cervical cancer, can be more accurately analyzed.

The invention relates to an Axitinib sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of Axitinib and sustained-release excipients and a certain amount of sustained-release regulator. The solid tumors include the liver cancer, the lung cancer, the esophageal canner, the gastric canner, the breast canner, the ovarian canner, the prostate canner, the bladder canner and the rectum canner. The sustained-release excipients are mainly a copolymer of polylactic acid, glycollic acid and hydroxyacetic acid and one of the three materials, polifeprosan, poly-(L-lactide-co-ethyl phosphonate) and Poly(L-lactide-co-propyl phosphonate) or a combination of the three materials, in the degradation and absorption process of which the Axitinib is sustainedly released to part of the tumor, thus the entire toxicity of the Axitinib is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the Axitinib, but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.

The invention relates to a bertschtinib sustained-release implant for treating solid tumors, which is characterized in the sustained-release implant contains anti-cancer effective dose of bertschtinib, sustained-released auxiliary materials and a certain amount of sustained-release regulator. Solid tumors comprise lung cancer, esophageal cancer, gastric cancer, liver cancer, mammary cancer, oophoroma, prostatic cancer, carcinoma of urinary bladder and colorectal cancer. The sustained-released auxiliary materials are mainly one or composition of the copolymer of glycolic acid and glycollic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate) and poly (L-lactide-co- propyl phosphate), which can slowly release bertschtinib to the tumor local during degeneration and absorption, thus keeping concentration of effective medicine in the part of the tumor while distinctively reducing overall toxic reaction. Putting the sustained-release implant in the tumor can not only reduce overall toxic reaction of bertschtinib, but also selectively improve drug concentration in the part of the tumor, thereby promoting treatment effect of non-operative treatment, such as chemotherapeutics, radiotherapy, etc.

The invention relates to the technical field of medical instruments, and discloses a vagina source application device. The device comprises a source applicator and a fixing device which are in slidingconnection, the fixing device is further provided with a locking piece used for limiting movement of the source applicator, the source applicator comprises a source application part and an adjustingpart which are connected, scales are arranged on an adjusting part, and a catheter channel penetrating through the source application part and the adjusting part and allowing the catheter connected with the source applicator and a radiotherapy machine to pass through is formed in the source application part and the adjusting part. The fixing device comprises a fixing plate and a fixing belt; wherein the fixing plate is attached to the perineum of a patient, a plurality of fixing grooves are formed in the fixing plate, the fixing belt comprises a first fixing part and a second fixing part, thefirst fixing part and the second fixing part define a fixing waistband, the fixing waistband is annularly arranged on the waist of the patient, a plurality of fixing pull belts are connected to the lower portion of the fixing waistband, and the fixing pull belts correspond to the fixing grooves one to one. According to the technical scheme, the vagina source application device is simple in structure, convenient to use, low in cost, accurate in positioning and easy to position and fix.

The invention provides a breast cancer patient radiotherapy tissue equivalent filler fixing device. The breast cancer patient radiotherapy tissue equivalent filler fixing device is composed of fillers, a pressing band, limiting holes, clips, unit parts, ventilating holes, trapezoid-shaped canvas, Velcro and a fixing pin, wherein the ventilating holes are formed in the trapezoid-shaped canvas, one end of the trapezoid-shaped canvas is connected with the Velcro, and the other end of the trapezoid-shaped canvas is provided with a row of unit parts with the limiting holes; the two ends of the pressing band are connected with the clips; the fillers 1 are located between two trapezoid-shaped canvas sheets and are fixed through the clips. The breast cancer patient radiotherapy tissue equivalent filler fixing device can better eliminate gaps between the body of a patient and the fillers and can further improve target region dosage except that close fitting is achieved. The breast cancer patient radiotherapy tissue equivalent filler fixing device can ensure more even whole-field radioactive ray dosage distribution and reduce irradiation field position deviations caused by involuntary movement of the patient after an irradiation body position is kept by the patient for a long time so as to smoothly finish irradiation. The breast cancer patient radiotherapy tissue equivalent filler fixing device is reasonable in design and easy to produce, achieves complex fitting of a physiological curved surface structure, is easy to operate when being used, and is suitable for tissue equivalent filler fixing in the breast cancer patient radiotherapy process.

A sustained release implant includes 0.1%-50% (w / w) nilotinib, 50-99% sustained release excipients and 0-15% sustained release moderator. Sustained release excipients are one or the combination of poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co- phosphoric acid propyl), glycolic acid and copolymer of glycolic acid and hydroxyacetic acid, and polifeprosan; sustained release moderator is one or combination of mannitol, sorbic alcohol and chondroitin; sustained release implant applied in local tumor can slowly release nilotinib onto local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction, thus the invention not only reduces overall toxic reaction of nilotinib, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy. The implant can be used for treating solid tumors including lung cancer, esophageal carcinoma, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic carcinoma, pancreatic cancer, bladder carcinoma, cerebroma, and colorectal cancer.

A material for brachytherapy is provided comprising a substrate having a longitudinal axis and a latitudinal, wherein the substrate comprises alternating peaks and valleys which are parallel to the longitudinal axis, the alternating peaks and valleys defining latitudinally extending pleats; and a plurality of medicament moieties positioned on the peaks and valleys of the substrate.

The invention relates to a controlled-release medicine preparation for treatment of local advanced rectal cancer. The controlled-release medicine preparation is prepared by using capecitabine as a medicinal effective ingredient and using a radiosensitive colon targeting drug vector, and is jointly applied with radiotherapy for treating local advanced rectal cancer, so that the treatment effect is improved, and toxic and side effects are reduced.